{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:19:41Z","timestamp":1777454381859,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Spanish Melanoma Group"},{"DOI":"10.13039\/501100004593","name":"Universidad Aut\u00f3noma de Madrid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy based on anti-PD1 inhibitors has significantly improved survival in advanced melanoma. However, a significant proportion of patients do not benefit, and predicting response to immunotherapy remains an area of unmet need. Our group previously defined an immune signature able to predict response to anti-PD1 inhibitors in this scenario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we analyzed two cohorts of patients with advanced melanoma treated with anti-PD1 inhibitors: the GEM cohort, previously used to validate our immune signature, and Campbell\u2019s cohort, which contains data about different immunotherapy schemes. Using the 107 genes that compose our immune signature and consensus clustering, samples were classified as immune-low or immune-high. Then, CIBERSORTx and Ecotyper were used to estimate the proportion of each immune cell type and carcinoma ecotypes in both cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We confirmed that the immune-low group includes mostly patients who do not response to anti-PD1 inhibitors. We also studied the distribution of carcinoma ecotypes in the immune-high and immune-low groups defined by our immune classification. Ecotypes CE9 and CE10 clustered in the immune-high group, with good response to treatment. The use of combination immunotherapy improved response rate both in immune-low and immune-high tumors. The immune-high group contained a higher number of CD8 T cells, B memory cells and T follicular helper cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our immune-based classification defines an immune-low group of tumors with poor response to anti-PD1 inhibitors. This immune classification is related to carcinoma ecotypes. Finally, a use of a combo scheme improves the rates of response both in immune-high and low groups but in the case of immune-low tumors, our results suggests that a combo treatment approach could be an adequate strategy and should be further explored in these patients. Altogether, our results support the utility of our immune signature in the prediction of response to anti-PD1 inhibitors in advanced melanoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-026-04392-1","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:56:18Z","timestamp":1777380978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy"],"prefix":"10.1007","volume":"75","author":[{"given":"Angelo","family":"G\u00e1mez-Pozo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Trilla-Fuertes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Becerril-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Lalanda-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virtudes","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Garicano Goldaraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Jos\u00e9","family":"Lecumberri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Rodr\u00edguez de la Borbolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"P\u00e9rez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Gonz\u00e1lez-Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juana","family":"Oramas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"L\u00f3pez-Vacas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Magdaleno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Fra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Mart\u00edn-Carnicero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Pu\u00e9rtolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Ramos-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan \u00c1ngel","family":"Fresno Vara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"1","key":"4392_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","volume":"36","author":"T Amaral","year":"2025","unstructured":"Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M et al (2025) Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 36(1):10\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.006","journal-title":"Ann Oncol"},{"key":"4392_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010801","author":"L Trilla-Fuertes","year":"2023","unstructured":"Trilla-Fuertes L, G\u00e1mez-Pozo A, Prado-V\u00e1zquez G, L\u00f3pez-Vacas R, Zapater-Moros A, L\u00f3pez-Camacho E et al (2023) Sorting transcriptomics immune information from tumor molecular features allows prediction of response to anti-PD1 therapy in patients with advanced melanoma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24010801","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4392_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F et al (2019) Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol 37(7):773\u2013782. https:\/\/doi.org\/10.1038\/s41587-019-0114-2","journal-title":"Nat Biotechnol"},{"issue":"21","key":"4392_CR4","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1016\/j.cell.2021.09.014","volume":"184","author":"BA Luca","year":"2021","unstructured":"Luca BA, Steen CB, Matusiak M, Azizi A, Varma S, Zhu C et al (2021) Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell 184(21):5482\u201396.e28. https:\/\/doi.org\/10.1016\/j.cell.2021.09.014","journal-title":"Cell"},{"key":"4392_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174407","author":"L Trilla-Fuertes","year":"2023","unstructured":"Trilla-Fuertes L, G\u00e1mez-Pozo A, Prado-V\u00e1zquez G, L\u00f3pez-Vacas R, Soriano V, Garicano F et al (2023) Multi-omics characterization of response to PD-1 inhibitors in advanced melanoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15174407","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4392_CR6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ccell.2023.03.010","volume":"41","author":"KM Campbell","year":"2023","unstructured":"Campbell KM, Amouzgar M, Pfeiffer SM, Howes TR, Medina E, Travers M et al (2023) Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell 41(4):791-806.e4. https:\/\/doi.org\/10.1016\/j.ccell.2023.03.010","journal-title":"Cancer Cell"},{"key":"4392_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/genes14020267","author":"AI Hafez","year":"2023","unstructured":"Hafez AI, Soriano B, Elsayed AA, Futami R, Ceprian R, Ramos-Ruiz R et al (2023) Client applications and server-side Docker for management of RNASeq and\/or VariantSeq workflows and pipelines of the GPRO suite. Genes. https:\/\/doi.org\/10.3390\/genes14020267","journal-title":"Genes"},{"key":"4392_CR8","doi-asserted-by":"publisher","first-page":"bar030","DOI":"10.1093\/database\/bar030","volume":"2011","author":"RJ Kinsella","year":"2011","unstructured":"Kinsella RJ, K\u00e4h\u00e4ri A, Haider S, Zamora J, Proctor G, Spudich G et al (2011) Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford) 2011:bar030. https:\/\/doi.org\/10.1093\/database\/bar030","journal-title":"Database (Oxford)"},{"issue":"9","key":"4392_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T et al (2016) The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13(9):731\u2013740. https:\/\/doi.org\/10.1038\/nmeth.3901","journal-title":"Nat Methods"},{"issue":"12","key":"4392_CR10","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN (2010) ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26(12):1572\u20131573. https:\/\/doi.org\/10.1093\/bioinformatics\/btq170","journal-title":"Bioinformatics"},{"issue":"1","key":"4392_CR11","doi-asserted-by":"publisher","first-page":"9968","DOI":"10.1038\/s41467-025-65016-3","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Li T, Eljilany I, Soupir A, Radmacher M, Agius P et al (2025) Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. Nat Commun 16(1):9968. https:\/\/doi.org\/10.1038\/s41467-025-65016-3","journal-title":"Nat Commun"},{"issue":"12","key":"4392_CR12","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L et al (2019) Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med 25(12):1916\u20131927. https:\/\/doi.org\/10.1038\/s41591-019-0654-5","journal-title":"Nat Med"},{"key":"4392_CR13","doi-asserted-by":"crossref","unstructured":"Reijers ILM, Dimitriadis P, Rozeman EA, JM Versluis, Broeks A, Bosch LJW, Bouwman J, Cornelissen S, Krijgsman O, Gonzalez M, Rao D, Grijpink-Ongering LG, van Dijk M, Spillane A, Scolyer RA, Van De Wiel BA, Menzies AM, Van Akkooi ACJ, Long GV, Blank CU (2021) DOMINI study: personalized combinations of neoadjuvant dominostat, nivolumab and ipilimumab in macroscopic stage III melanoma based on the IFN-gamma signature. ESMO Congress","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS10087"},{"issue":"8","key":"4392_CR14","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al (2017) IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127(8):2930\u20132940. https:\/\/doi.org\/10.1172\/JCI91190","journal-title":"J Clin Invest"},{"issue":"9","key":"4392_CR15","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1172\/JCI87324","volume":"126","author":"AI Daud","year":"2016","unstructured":"Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K et al (2016) Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest 126(9):3447\u20133452. https:\/\/doi.org\/10.1172\/JCI87324","journal-title":"J Clin Invest"},{"issue":"suppl_12","key":"4392_CR16","doi-asserted-by":"publisher","first-page":"xii44","DOI":"10.1093\/annonc\/mdx237","volume":"28","author":"AR S\u00e1nchez-Paulete","year":"2017","unstructured":"S\u00e1nchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, P\u00e9rez-Gracia JL, S\u00e1nchez-Arr\u00e1ez A et al (2017) Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol 28(suppl_12):xii44\u2013xii55. https:\/\/doi.org\/10.1093\/annonc\/mdx237","journal-title":"Ann Oncol"},{"issue":"3","key":"4392_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133\u2013150. https:\/\/doi.org\/10.1038\/s41568-019-0116-x","journal-title":"Nat Rev Cancer"},{"issue":"7528","key":"4392_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568\u2013571. https:\/\/doi.org\/10.1038\/nature13954","journal-title":"Nature"},{"issue":"4","key":"4392_CR19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW et al (2018) Defining T Cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175(4):998-1013.e20. https:\/\/doi.org\/10.1016\/j.cell.2018.10.038","journal-title":"Cell"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04392-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:56:22Z","timestamp":1777380982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04392-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4392"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04392-1","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval from the Ethics Committee of Comunidad Foral de Navarra was obtained (EO17\/23). All the experiments followed the relevant guidelines and recommendations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained for all the participants in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"156"}}